| Literature DB >> 36005226 |
Dalal Hammoudi Halat1, Samar Younes2, Jihan Safwan2, Zeina Akiki3,4, Marwan Akel4,5, Mohamad Rahal1.
Abstract
COVID-19 has impacted mental health and affected education due to the shift to remote learning. The purpose of the current study was to assess the mental health of pharmacy students one year following the onset of the pandemic. A descriptive cross-sectional questionnaire was distributed to pharmacy students. The severity of depression, anxiety, and stress was assessed by the Depression Anxiety Stress Scale (DASS-21), and resilience was assessed by the Brief Resilience Scale (BRS). COVID-19-related economic, educational, and health stressors, and students' vaccine attitudes were surveyed. Descriptive, bivariate, and multivariable analysis were used, and a p-value of <0.05 was considered significant. A total of 561 students participated; 37% had mild-to-moderate depression, 37% had severe-to-extremely-severe anxiety, and 52% demonstrated normal stress levels. Severe depression, anxiety, and stress were associated with smoking and feeling isolated due to COVID-19. Around 40% of students had low resilience, associated with smoking, being in the third or fourth year of pharmacy study, and the consumption of caffeinated beverages. The mean score of satisfaction with online learning was 60.3 ± 21.3%. Only 5% of participants were vaccinated, of which 87% trusted the benefits of vaccines and their role in controlling the pandemic. One year after the onset of COVID-19, depression, anxiety, stress, and low resilience were observed among pharmacy students; the investigation of the long-term mental effects of the pandemic on university students is warranted.Entities:
Keywords: BRS; COVID-19; DASS-21; mental health; pharmacy education; pharmacy students
Year: 2022 PMID: 36005226 PMCID: PMC9407568 DOI: 10.3390/ejihpe12080077
Source DB: PubMed Journal: Eur J Investig Health Psychol Educ ISSN: 2174-8144
Sociodemographic characteristics of participants and reported lifestyle changes in relation to COVID-19.
|
| Female | 428 (76.3) |
|
| 22 (20; 23) | |
|
| 17–42 | |
|
| Lebanese | 532 (94.8) |
| Non-Lebanese | 29 (5.2) | |
|
| Beirut | 131 (23.4) |
| Baalbek-Hermel and Bekaa | 144 (25.7) | |
| Mount Lebanon | 118 (21) | |
| Nabatieh and South | 81 (14.4) | |
| North and Akkar | 80 (14.3) | |
| Residing currently out of Lebanon | 7 (1.2) | |
|
| Single | 524 (93.4) |
| Married | 35 (6.2) | |
| Widowed/Divorced | 2 (0.4) | |
|
| One to two persons | 22 (3.9) |
| Three to five | 351 (62.6) | |
| Six or more | 188 (33.5) | |
|
| First or second | 174 (31) |
| Third or fourth | 219 (39) | |
| Fifth or PharmD | 168 (29.9) | |
|
| No | 445 (79.3) |
| <10 cigarettes per day and/or <3 shisha per week | 66 (11.8) | |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 50 (8.9) | |
|
| No | 148 (26.4) |
| Less than two cups per day | 254 (45.4) | |
| Two cups or more per day | 158 (28.2) | |
|
| No | 477 (85) |
| Once per week | 61 (10.9) | |
| More than once per week | 23 (4.1) | |
|
| No | 484 (86.3) |
| Once every few weeks | 59 (10.5) | |
|
| No changes | 161 (28.7) |
| Gained weight | 181 (32.3) | |
| Lost weight | 219 (39) | |
|
| <2,000,000 | 126 (22.5) |
| [2,000,000–4,000,000] | 199 (35.5) | |
| [4,000,001–6,000,000] | 123 (21.9) | |
| >6,000,000 | 113 (20.1) | |
|
| Yes | 407 (72.5) |
|
| Yes | 97 (17.3) |
COVID-19, Coronavirus disease 2019; LBP, Lebanese pounds; Q1, first quartile; Q3, third quartile.
Figure 1Flow chart describing the study’s steps and methodology. DASS21: Depression, Anxiety, and Stress Scale 21 Items; BRS: Brief Resilience Scale; COVID-19: Coronavirus Disease 2019.
Health- and COVID-19-related information of the participants.
|
| ||
|
| Yes | 118 (21) |
|
| Yes | 72 (12.8) |
|
| Yes | 84 (15) |
|
| Yes | 168 (29.9) |
|
| Yes | 17 (3) |
|
| Yes | 72 (12.8) |
|
| Yes | 127 (22.6) |
|
| Yes | 10 (7.9) |
|
| Yes | 51 (41.2) |
|
| Yes | 128 (22.8) |
|
| Yes | 346 (61.7) |
|
| No | 346 (61.7) |
| Yes with mild to moderate symptoms | 157 (28) | |
| Yes with severe symptoms or hospitalization | 58 (10.3) | |
|
| No | 236 (42.1) |
| Yes with mild to moderate symptoms | 169 (30.1) | |
| Yes with severe symptoms or hospitalization | 156 (27.8) | |
|
| Never | 61 (10.9) |
| Rarely | 123 (21.9) | |
| Usually | 255 (45.5) | |
| Always | 122 (21.7) | |
|
| Yes | 30 (5.3) |
|
| Sputnik V | 5 (16.7) |
| Sinopharm | 3 (10) | |
| Pfizer | 21 (70) | |
| AstraZeneca | 1 (3.3) | |
|
| No | 0 |
| Yes | 26 (86.7) | |
| Somewhat | 4 (13.7) | |
|
| No | 13 (43.3) |
| Yes | 11 (36.7) | |
| Somewhat | 6 (20) | |
|
| No | 13 (43.3) |
| Yes | 9 (30) | |
| Somewhat | 8 (26.7) | |
|
| No | 531 (94.7) |
|
| No | 76 (14.3) |
| Yes | 330 (62.1) | |
| Maybe | 125 (23.5) | |
|
| No | 61 (11.6) |
| Yes | 310 (59) | |
| Somewhat | 154 (29.3) | |
|
| No | 161 (30.4) |
| Yes | 183 (34.5) | |
| Somewhat | 186 (35.1) | |
|
| No | 278 (52.5) |
| Yes | 92 (17.4) | |
| Somewhat | 160 (30.2) |
COVID-19, Coronavirus disease 2019; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs.
Results of DASS-21 and BRS analysis of the participants.
| Scale | Result | |
|---|---|---|
| DASS-21 | ||
|
| Normal | 202 (36) |
| Mild to moderate | 210 (37.4) | |
| Severe to extremely severe | 149 (26.6) | |
|
| Normal | 164 (29.2) |
| Mild to moderate | 191 (34) | |
| Severe to extremely severe | 206 (36.7) | |
|
| Normal | 290 (51.7) |
| Mild to moderate | 172 (30.7) | |
| Severe to extremely severe | 99 (17.6) | |
| BRS scale | Low | 221 (39.4) |
| Normal to high | 340 (60.6) |
DASS-21, Depression, Anxiety, and Stress Scale; BRS, Brief Resilience Scale.
Bivariate associations for DASS-21 subscales.
| Depression Subscale | Anxiety Subscale | Stress Subscale | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Normal | Mild to Moderate | Severe to Extremely Severe | Normal | Mild to Moderate | Severe to Very Severe | Normal | Mild to Moderate | Severe to Very Severe | |
|
| |||||||||
| Male | 52 (39.1 | 45 (33.8) | 36 (27.1) | 47 (35.3) | 43 (32.3) | 43 (32.3) | 71 (53.4) | 41 (30.8) | 21 (15.8) |
| Female | 150 (35) | 165 (38.6) | 113 (26.4) | 117 (27.3) | 148 (34.6) | 163 (38.1) | 219 (51.2) | 131 (30.6) | 78 (18.2) |
|
| 202 (22.3 ± 3.6) | 210 (21.8 ± 2.6) | 148 (21.7 ± 2.6) | 164 (22.3 ± 3.8) | 191 (22.0 ± 2.8) | 205 (21.8 ± 2.5) | 289 (22 ± 3.4) | 172 (22 ± 2.3) | 99 (21.6 ± 2.9) |
|
| |||||||||
| Lebanese | 192 (36.1) | 198 (37.2) | 142 (26.7) | 153 (28.8) | 181 (34) | 198 (37.2) | 273 (51.3) | 167 (31.4) | 92 (17.3) |
| Non-Lebanese | 10 (34.5) | 12 (41.4) | 7 (24.1) | 11 (37.9) | 10 (34.5) | 8 (27.6) | 17 (58.6) | 5 (17.2) | 7 (24.1) |
|
| |||||||||
| Beirut | 48 (36.6) | 47 (35.9) | 36 (27.5) | 36 (27.5) | 43 (32.8) | 52 (39.7) | 67 (51.1) | 40 (30.5) | 24 (18.3) * |
| Baalbek-Hermel and Bekaa | 46 (31.9) | 51 (35.4) | 47 (32.6) | 33 (22.9) | 47 (32.6) | 64 (44.4) | 66 (45.8) | 42 (29.2) | 36 (25) |
| Mount Lebanon | 49 (41.5) | 41 (34.7) | 28 (23.7) | 40 (33.9) | 48 (40.7) | 30 (25.4) | 72 (61) | 27 (22.9) | 19 (16.1) |
| Nabatieh and South | 27 (33.3) | 40 (49.4) | 14 (17.3) | 25 (30.9) | 32 (39.5) | 24 (29.6) | 38 (46.9) | 31 (38.3) | 12 (14.8) |
| North and Akkar | 30 (37.5) | 30 (37.5) | 20 (25) | 28 (35) | 20 (25) | 32 (40) | 45 (56.3) | 27 (33.8) | 8 (10) |
| Currently out of Lebanon | 2 (28.6) | 1 (14.3) | 4 (57.1) | 2 (28.6) | 1 (14.3) | 4 (57.1) | 2 (28.6) | 5 (71.4) | 0 |
|
| |||||||||
| Single | 188 (35.9) | 197 (37.6) | 139 (26.5) | 154 (29.4) | 180 (34.4) | 190 (36.3) | 268 (51.1) | 161 (30.7) | 95 (18.1) |
| Married | 13 (37.1) | 13 (37.1) | 9 (25.7) | 10 (28.6) | 10 (28.6) | 15 (42.9) | 21 (60) | 11 (31.4) | 3 (8.6) |
| Widow/Divorced | 1 (50) | 0 | 1 (50) | 0 | 1 (50) | 1 (50) | 1 (50) | 0 | 1 (50) |
|
| |||||||||
| One to two persons | 6 (27.3) | 4 (18.2) | 12 (54.5) * | 6 (27.3) | 5 (22.7) | 11 (50) | 11 (50) | 6 (27.3) | 5 (22.7) |
| Three to five | 123 (35) | 136 (38.7) | 92 (26.2) | 104 (29.6) | 118 (33.6) | 129 (36.8) | 184 (52.4) | 105 (29.9) | 62 (17.7) |
| Six or more | 73 (38.8) | 70 (37.2) | 45 (23.9) | 54 (28.7) | 68 (36.2) | 66 (35.1) | 95 (50.5) | 61 (32.4) | 32 (17) |
|
| |||||||||
| First or second | 63 (36.2) | 67 (38.5) | 44 (25.3) | 56 (32.2) | 61 (35.1) | 57 (32.8) ** | 100 (57.5) | 43 (24.7) | 31 (17.8) ** |
| Third or fourth | 73 (33.3) | 83 (37.9) | 63 (28.8) | 46 (21) | 78 (35.6) | 95 (43.4) | 92 (42) | 83 (37.9) | 44 (20.1) |
| Fifth or PharmD | 66 (39.3) | 60 (35.7) | 42 (25) | 62 (36.9) | 52 (31) | 54 (32.1) | 98 (58.3) | 46 (27.4) | 24 (14.3) |
|
| |||||||||
| No | 170 (38.2) | 165 (37.1) | 110 (24.7) * | 133 (29.9) | 155 (34.8) | 157 (35.3) | 244 (54.8) | 125 (28.1) | 76 (17.1) ** |
| <10 cigarettes per day and/or <3 shisha per week | 23 (34.8) | 24 (36.4) | 19 (28.8) | 21 (31.8) | 19 (28.8) | 26 (39.4) | 33 (50) | 23 (34.8) | 10 (15.2) |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 9 (18) | 21 (42) | 20 (40) | 10 (20) | 17 (34) | 23 (46) | 13 (26) | 24 (48) | 13 (26) |
|
| |||||||||
| No | 57 (38.5) | 60 (40.5) | 31 (20.9) | 48 (32.4) | 53 (35.8) | 47 (31.8) * | 83 (56.1) | 44 (29.7) | 21 (14.2) * |
| Less than two cups per day | 100 (39.4) | 88 (34.6) | 66 (26) | 78 (30.7) | 93 (36.6) | 83 (32.7) | 138 (54.3) | 78 (30.7) | 38 (15) |
| Two cups or more per day | 45 (28.5) | 61 (38.6) | 52 (32.9) | 38 (24.1) | 44 (27.8) | 76 (48.1) | 69 (43.7) | 49 (31) | 40 (25.3) |
|
| |||||||||
| No | 178 (37.3) | 176 (36.9) | 123 (25.8) | 144 (30.2) | 161 (33.8) | 172 (36.1) | 252 (52.8) | 139 (29.1) | 86 (18) |
| Once per week | 19 (31.1) | 25 (41) | 17 (27.9) | 17 (27.9) | 22 (36.1) | 22 (36.1) | 31 (50.8) | 22 (36.1) | 8 (13.1) |
| More than once per week | 5 (21.7) | 9 (39.1) | 9 (39.1) | 3 (13) | 8 (34.8) | 12 (52.2) | 7 (30.4) | 11 (47.8) | 5 (21.7) |
|
| |||||||||
| No | 180 (37.2) | 189 (39) | 115 (23.8) ** | 141 (29.1) | 169 (34.9) | 174 (36) | 262 (54.1) | 142 (29.3) | 80 (16.5) * |
| Once every few weeks | 14 (23.7) | 17 (28.8) | 28 (47.5) | 16 (27.1) | 18 (30.5) | 25 (42.4) | 20 (33.9) | 23 (39) | 16 (27.1) |
| On a weekly basis | 8 (44.4) | 4 (22.2) | 6 (33.3) | 7 (38.9) | 4 (22.2) | 7 (38.9) | 8 (44.4) | 7 (38.9) | 3 (16.7) |
|
| |||||||||
| No changes | 78 (48.5) | 62 (38.5) | 21 (13) *** | 60 (37.3) | 56 (34.8) | 45 (28) * | 105 (65.2) | 41 (25.5) | 15 (9.3) ** |
| Gained weight | 65 (35.9) | 56 (30.9) | 60 (33.1) | 49 (27.1) | 56 (30.9) | 76 (42) | 87 (48.1) | 57 (31.5) | 37 (20.4) |
| Lost weight | 59 (26.9) | 92 (42) | 68 (31.1) | 55 (25.1) | 79 (36.1) | 85 (38.8) | 98 (44.7) | 74 (33.8) | 47 (21.5) |
|
| |||||||||
| <2,000,000 | 37 (29.4) | 56 (44.4) | 33 (26.2) | 32 (25.4) | 39 (31) | 55 (43.7) | 60 (47.6) | 44 (34.9) | 22 (17.5) |
| [2,000,000–4,000,000] | 74 (37.2) | 64 (32.2) | 61 (30.7) | 52 (26.1) | 74 (37.2) | 73 (36.7) | 102 (51.3) | 58 (29.1) | 39 (19.6) |
| [4,000,001–6,000,000] | 43 (35) | 54 (43.9) | 26 (21.1) | 41 (33.3) | 40 (32.5) | 42 (34.1) | 65 (52.8) | 43 (35) | 15 (12.2) |
| >6,000,000 | 48 (42.5) | 36 (31.9) | 29 (25.7) | 39 (34.5) | 38 (33.6) | 36 (31.9) | 63 (55.8) | 27 (23.9) | 23 (20.4) |
|
| |||||||||
| No | 58 (37.7) | 64 (41.6) | 32 (20.8) | 48 (31.2) | 58 (37.7) | 48 (31.2) | 78 (50.6) | 55 (35.7) | 21 (13.6) |
| Yes | 144 (35.4) | 146 (35.9) | 117 (28.7) | 116 (28.5) | 133 (32.7) | 158 (38.8) | 212 (52.1) | 117 (28.7) | 78 (19.2) |
|
| |||||||||
| No | 171 (36.9) | 170 (36.6) | 123 (26.5) | 136 (29.3) | 160 (34.5) | 168 (36.2) | 237 (51.1) | 149 (32.1) | 78 (16.8) |
| Yes | 31 (32) | 40 (41.2) | 26 (26.8) | 28 (28.9) | 31 (32) | 38 (39.2) | 53 (54.6) | 23 (23.7) | 21 (21.6) |
|
| |||||||||
| No | 171(38.6) | 164 (37) | 108 (24.4) * | 142 (32.1) | 157 (35.4) | 144 (32.5) *** | 243 (54.9) | 133 (30) | 67 (15.1) ** |
| Yes | 31 (26.3) | 46 (39) | 41 (34.7) | 22 (18.6) | 34 (28.8) | 62 (52.5) | 47 (39.8) | 39 (33.1) | 32 (27.1) |
|
| |||||||||
| No | 184 (37.6) | 183 (37.4) | 122 (24.9) * | 153 (31.3) | 172 (35.2) | 164 (33.5) *** | 264 (54) | 150 (30.7) | 75 (15.3) *** |
| Yes | 18 (25) | 27 (37.5) | 27 (37.5) | 11 (15.3) | 19 (26.4) | 42 (58.3) | 26 (36.1) | 22 (30.6) | 24 (33.3) |
|
| |||||||||
| No | 184 (38.6) | 180 (37.7) | 113 (23.7) *** | 155 (32.5) | 163 (34.2) | 159 (33.3) *** | 259 (54.3) | 148 (31) | 70 (14.7) *** |
| Yes | 18 (21.4) | 30 (35.7) | 36 (42.9) | 9 (10.7) | 28 (33.3) | 47 (56) | 31 (36.9) | 24 (28.6) | 29 (34.5) |
|
| |||||||||
| No | 153 (38.9) | 147 (37.4) | 93 (23.7) * | 133 (33.8) | 143 (36.4) | 117 (29.8) *** | 220 (56) | 120 (30.5) | 53 (13.5) *** |
| Yes | 49 (29.2) | 63 (37.5) | 56 (33.3) | 31 (18.5) | 48 (28.6) | 89 (53) | 70 (41.7) | 52 (31) | 46 (27.4) |
|
| |||||||||
| No | 199 (36.6) | 204 (37.5) | 141 (25.9) | 163 (30) | 186 (34.2) | 195 (35.8) * | 288 (52.9) | 166 (30.5) | 90 (16.5) *** |
| Yes | 3 (17.6) | 6 (35.3) | 8 (47.1) | 1 (5.9) | 5 (29.4) | 11 (64.7) | 2 (11.8) | 6 (35.3) | 9 (52.9) |
|
| |||||||||
| No | 185 (37.8) | 182 (37.2) | 122 (24.9) * | 149 (30.5) | 166 (33.9) | 174 (35.6) | 262 (53.6) | 145 (29.7) | 82 (16.8) |
| Yes | 17 (23.6) | 28 (38.9) | 27 (37.5) | 15 (20.8) | 25 (34.7) | 32 (44.4) | 28 (38.9) | 27 (37.5) | 17 (23.6) |
|
| |||||||||
| No | 155 (35.7) | 159 (36.6) | 120 (27.6) | 124 (28.6) | 147 (33.9) | 163 (37.6) | 223 (51.4) | 128 (29.5) | 83 (19.1) |
| Yes | 47 (37) | 51 (40.2) | 29 (22.8) | 40 (31.5) | 44 (34.6) | 43 (33.9) | 67 (52.8) | 44 (34.6) | 16 (12.6) |
|
| |||||||||
| No | 171 (39.5) | 150 (34.6) | 112 (25.9) ** | 139 (32.1) | 147 (33.9) | 147 (33.9) ** | 228 (52.7) | 128 (29.6) | 77 (17.8) |
| Yes | 31 (24.2) | 60 (46.9) | 37 (28.9) | 25 (19.5) | 44 (34.4) | 59 (46.1) | 62 (48.4) | 44 (34.4) | 22 (17.2) |
|
| |||||||||
| No | 93 (43.3) | 72 (33.5) | 50 (23.3) * | 74 (34.4) | 75 (34.9) | 66 (30.7) * | 126 (58.6) | 58 (27) | 31 (14.4) * |
| Yes | 109 (31.5) | 138 (39.9) | 99 (28.6) | 90 (26) | 116 (33.5) | 140 (40.5) | 164 (47.4) | 114 (32.9) | 68 (19.7) |
|
| |||||||||
| No | 140 (40.5) | 114 (32.9) | 92 (26.6) * | 115 (33.2) | 118 (34.1) | 113 (32.7) *** | 185 (53.5) | 103 (29.8) | 58 (16.8) |
| Yes, mild to moderate symptoms | 45 (28.7) | 75 (47.8) | 37 (23.6) | 36 (22.9) | 63 (40.1) | 58 (36.9) | 81 (51.6) | 53 (33.8) | 23 (14.6) |
| Yes, severe symptoms or hospitalization | 17 (29.3) | 21 (36.2) | 20 (34.5) | 13 (22.4) | 10 (17.2) | 35 (60.3) | 24 (41.4) | 16 (27.6) | 18 (31) |
|
| |||||||||
| No | 94 (39.8) | 80 (33.9) | 62 (26.3) ** | 84 (35.6) | 83 (35.2) | 69 (29.2) ** | 124 (52.5) | 71 (30.1) | 41 (17.4) |
| Yes, mild to moderate symptoms | 72 (42.6) | 55 (32.5) | 42 (24.9) | 52 (30.8) | 54 (32) | 63 (37.3) | 93 (55) | 47 (27.8) | 29 (17.2) |
| Yes, severe symptoms or hospitalization | 36 (23.1) | 75 (48.1) | 45 (28.8) | 28 (17.9) | 54 (34.6) | 74 (47.4) | 73 (46.8) | 54 (34.6) | 29 (18.6) |
|
| |||||||||
| Never | 38 (62.3) | 17 (27.9) | 6 (9.8) *** | 30 (49.2) | 17 (27.9) | 14 (23) *** | 45 (73.8) | 13 (21.3) | 3 (4.9) *** |
| Rarely | 58 (47.2) | 51 (41.5) | 14 (11.4) | 44 (35.8) | 50 (40.7) | 29 (23.6) | 75 (61) | 39 (31.7) | 9 (7.3) |
| Usually | 81 (31.8) | 96 (37.6) | 78 (30.6) | 62 (24.3) | 90 (35.3) | 103 (40.4) | 118 (46.3) | 85 (33.3) | 52 (20.4) |
| Always | 25 (20.5) | 46 (37.7) | 51 (41.8) | 28 (23) | 34 (27.9) | 60 (49.2) | 52 (42.6) | 35 (28.7) | 35 (28.7) |
|
| |||||||||
| No | 192 (36.2) | 197 (37.1) | 142 (26.7) | 156 (29.4) | 177 (33.3) | 198 (37.3) | 270 (50.8) | 165 (31.1) | 96 (18.1) |
| Yes | 10 (33.3) | 13 (43.3) | 7 (23.3) | 8 (26.7) | 14 (46.7) | 8 (26.7) | 20 (66.7) | 7 (23.3) | 3 (10) |
For the bivariate analysis: p < 0.05 *, p < 0.01 **, p < 0.001 ***. COVID-19, Coronavirus disease 2019; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs; LBP, Lebanese pounds.
Multivariable associations for DASS-21 subscales.
| Adjusted OR | |||
|---|---|---|---|
| Multivariable Associations for the Depression Subscale— | |||
|
| |||
|
| No | Reference | |
| <10 cigarettes per day and/or <3 shisha per week | 1.14 (0.58; 2.25) | 0.7 | |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 2.72 (1.13; 6.54) |
| |
|
| Never | Reference | |
| Rarely | 1.67 (0.80; 3.50) | 0.2 | |
| Usually | 2.47 (1.23; 4.95) |
| |
| Always | 4.21 (1.87; 9.46) |
| |
|
| 2.12 (1.06; 4.28) |
| |
|
| |||
|
| No | Reference | |
| <10 cigarettes per day and/or <3 shisha per week | 1.009 (0.46; 2.22) | 0.9 | |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 3.32 (1.30; 8.52) |
| |
|
| No changes | Reference | |
| Gained weight | 2.37 (1.22; 4.63) |
| |
| Lost weight | 3.47 (1.80; 6.67) |
| |
|
| 3.93 (1.84; 8.38) |
| |
|
| Never | Reference | |
| Rarely | 1.009 (0.33; 3.08) | 0.9 | |
| Usually | 5.32 (1.99; 14.2) |
| |
| Always | 11.1 (3.84; 32) |
| |
|
| |||
|
| |||
|
| Never | Reference | |
| Rarely | 1.70 (0.80; 3.62) | 0.2 | |
| Usually | 2.01 (1.01; 4.23) |
| |
| Always | 1.76 (0.77; 4.01) | 0.2 | |
|
| |||
|
| No changes | Reference | |
| Gained weight | 1.55 (0.86; 2.80) | 0.1 | |
| Lost weight | 1.83 (1.03; 3.25) |
| |
|
| First or second | Reference | |
| Third or fourth | 1.30 (0.73; 2.30) | 0.4 | |
| Fifth or PharmD | 0.5 (0.28; 0.92) |
| |
|
| 1.86 (1.07; 3.21) |
| |
|
| Never | Reference | |
| Rarely | 1.20 (0.51; 2.82) | 0.7 | |
| Usually | 2.65 (1.21; 5.79) |
| |
| Always | 3.11 (1.32; 7.32) |
| |
|
| |||
|
| |||
|
| No | Reference | |
| <10 cigarettes per day and/or <3 shisha per week | 1.16 (0.60; 2.25) | 0.7 | |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 3.01 (1.42; 6.62) |
| |
|
| No changes | Reference | |
| Gained weight | 1.55 (0.90; 2.64) | 0.1 | |
| Lost weight | 1.85 (1.12; 3.08) |
| |
|
| First or second | Reference | |
| Third or fourth | 1.82 (1.10; 3.02) |
| |
| Fifth or PharmD | 0.88 (0.5; 1.54) | 0.7 | |
|
| Never | Reference | |
| Rarely | 1.61 (0.74; 3.51) | 0.2 | |
| Usually | 2.28 (1.10; 4.71) |
| |
| Always | 2.09 (0.93; 4.69) | 0.07 | |
|
| |||
|
| No changes | Reference | |
| Gained weight | 2.21 (1.05; 4.67) |
| |
| Lost weight | 3.11 (1.53; 6.32) |
| |
|
| 11.16 (1.94; 64.4) |
| |
|
| Never | Reference | |
| Rarely | 1.27 (0.30; 5.35) | 0.7 | |
| Usually | 4.81 (1.34; 17.3) |
| |
| Always | 7.10 (1.90; 26.6) |
| |
# Others = other than acetaminophen, antihistamines, NSAIDs, multivitamins or minerals, antidepressants or anxiolytics; COVID-19, Coronavirus disease 2019; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs; CI, Confidence interval.
Bivariate associations for BRS.
| Low | Normal to High | ||
|---|---|---|---|
|
| Male | 49 (36.8) | 84 (63.2) |
| Female | 172 (40.2) | 256 (59.8) | |
|
| 21.8 ± 2.52 | 22.1 ± 3.3 | |
|
| Lebanese | 212 (39.8) | 320 (60.2) |
| Non-Lebanese | 9 (31) | 20 (69) | |
|
| Beirut | 47 (35.9) | 84 (64.1) |
| Baalbek-Hermel and Bekaa | 68 (47.2) | 76 (52.8) | |
| Mount Lebanon | 43 (36.4) | 75 (63.6) | |
| Nabatieh and South | 28 (34.6) | 53 (65.4) | |
| North and Akkar | 30 (37.5) | 50 (62.5) | |
| Currently out of Lebanon | 5 (71.4) | 2 (28.6) | |
|
| Single | 213 (40.6) | 311 (59.4) |
| Married | 8 (22.9) | 27 (77.1) | |
| Widow/Divorced | 0 | 2 (100) | |
|
| One to two persons | 6 (27.3) | 16 (72.7) |
| Three to five | 139 (39.6) | 212 (60.4) | |
| Six or more | 76 (40.4) | 112 (59.6) | |
|
| First or second | 58 (33.3) | 116 (66.7) * |
| Third or fourth | 102 (46.6) | 117 (53.4) | |
| Fifth or PharmD | 61 (36.3) | 107 (63.7) | |
|
| No | 167 (37.5) | 278 (62.5) * |
| <10 cigarettes per day and/or <3 shisha per week | 26 (39.4) | 40 (60.6) | |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 28 (56) | 22 (44) | |
|
| No | 44 (29.7) | 104 (70.3) * |
| Less than two cups per day | 107 (42.1) | 147 (57.9) | |
|
| No | 185 (38.8) | 292 (61.2) |
| Once per week | 25 (41) | 36 (59) | |
| More than once per week | 11 (47.8) | 12 (52.2) | |
|
| No | 183 (37.8) | 301 (62.2) |
| Once every few weeks | 27 (45.8) | 32 (54.2) | |
|
| No | 50 (31.1) | 111 (68.9) * |
| Gained weight | 78 (43.1) | 103 (56.9) | |
| Lost weight | 93 (42.5) | 126 (57.5) | |
|
| <2,000,000 | 57 (45.2) | 69 (54.8) * |
| [2,000,000–4,000,000] | 86 (43.2) | 113 (56.8) | |
| [4,000,001–6,000,000] | 45 (36.6) | 78 (63.4) | |
| >6,000,000 | 33 (29.2) | 80 (70.8) | |
|
| No | 60 (39) | 94 (61) |
| Yes | 161 (39.6) | 246 (60.4) | |
|
| No | 187 (40.3) | 277 (59.7) |
| Yes | 34 (35.1) | 63 (64.9) | |
|
| No | 167 (37.7) | 276 (62.3) |
| Yes | 54 (45.8) | 64 (54.2) | |
|
| No | 187 (38.2) | 302 (61.8) |
| Yes | 34 (47.2) | 38 (52.8) | |
|
| No | 180 (37.7) | 297 (62.3) |
| Yes | 41 (48.8) | 43 (51.2) | |
|
| No | 143 (36.4) | 250 (63.6) * |
| Yes | 78 (46.4) | 90 (53.6) | |
|
| No | 209 (38.4) | 335 (61.6) ** |
| Yes | 12 (70.6) | 5 (29.4) | |
|
| No | 186 (38) | 303 (62) |
| Yes | 35 (48.6) | 37 (51.4) | |
|
| No | 177 (40.8) | 257 (59.2) |
| Yes | 44 (34.6) | 83 (65.4) | |
|
| No | 168 (38.8) | 265 (61.2) |
| Yes | 53 (41.4) | 75 (58.6) | |
|
| No | 77 (35.8) | 138 (64.2) |
| Yes | 144 (41.6) | 202 (58.4) | |
|
| No | 141 (40.8) | 205 (59.2) |
| Yes, mild to moderate symptoms | 56 (35.7) | 101 (64.3) | |
| Yes, severe symptoms or hospitalization | 24 (41.4) | 34 (58.6) | |
|
| No | 95 (40.3) | 141 (59.7) |
| Yes, mild to moderate symptoms | 61 (36.1) | 108 (63.9) | |
| Yes, severe symptoms or hospitalization | 65 (41.7) | 91 (58.3) | |
|
| Never | 22 (36.1) | 39 (63.9) ** |
| Rarely | 37 (30.1) | 86 (69.9) | |
| Usually | 99 (38.8) | 156 (61.2) | |
| Always | 63 (51.6) | 59 (48.4) | |
|
| No | 209 (39.4) | 322 (60.6) |
| Yes | 12 (40) | 18 (60) |
p < 0.05 *, p < 0.01 ** COVID-19, Coronavirus disease 2019; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs; LBP, Lebanese pounds.
Multivariable associations for BRS.
|
| Adjusted OR | ||
|---|---|---|---|
|
| First or second | Reference | |
| Third or fourth | 0.63 (0.41; 0.97) | 0.04 | |
| Fifth or PharmD | 0.99 (0.62; 1.59) | 0.9 | |
|
| No | Reference | |
| <10 cigarettes per day and/or <3 shisha per week | 1.10 (0.61; 1.97) | 0.7 | |
| ≥10 cigarettes per day and/or ≥3 shisha per week | 0.49 (0.26; 0.95) |
| |
|
| No | Reference | |
| Less than two cups per day | 0.54 (0.34; 0.85) |
| |
|
| <2,000,000 | Reference | |
| [2,000,000–4,000,000] | 0.97 (0.60; 1.56) | 0.9 | |
| [4,000,001–6,000,000] | 1.21 (0.71; 2.08) | 0.5 | |
| >6,000,000 | 1.97 (1.12; 3.47) |
| |
COVID-19, Coronavirus disease 2019; LBP, Lebanese pounds; BRS, Brief resilience scale; CI, Confidence interval.
Figure 2Satisfaction of participants with distance learning during COVID-19. The mean scores on the 5-point Likert scale were converted into percentages with a score of 0 corresponding to 0% and a score of 5 corresponding to 100%.